Ascendis Pharma A (ASND) Tax Provisions (2014 - 2026)

Ascendis Pharma A has reported Tax Provisions for 13 years, with the latest figure at $793.2 million in Q1 2026.

• Quarterly Tax Provisions rose 71172.03% year-over-year to $793.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $776.6 million (up 21422.79% YoY) and the FY2025 annual result came in at $46.2 million, up 992.78% from the prior year.
• Tax Provisions improved to $793.2 million in Q1 2026 per ASND's latest filing, from -$8.0 million in the prior quarter.
• Over five years, Tax Provisions peaked at $793.2 million in Q1 2026 and troughed at -$8.0 million in Q4 2025.
• A 5-year average of $44.6 million and a median of -$1.1 million in 2024 frame the typical range for Tax Provisions.
• The sharpest annual moves came in 2022 and 2026: Tax Provisions tumbled 4083.86% in 2022, then jumped 71172.03% in 2026.
• Over 5 years, Tax Provisions stood at -$5.5 million in 2022, then decreased by 14.19% to -$6.2 million in 2023, then jumped by 81.39% to -$1.2 million in 2024, then slumped by 588.43% to -$8.0 million in 2025, then surged by 10037.54% to $793.2 million in 2026.
• According to Business Quant data, Tax Provisions over the past three periods registered $793.2 million, -$8.0 million, and -$4.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.